EU wins arbitration in pharma trade dispute with Turkey
Reuters
Published Jul 25, 2022 12:20PM ET
GENEVA (Reuters) -The European Union received a largely favourable ruling in its trade dispute with Turkey on Monday in the first appeal settled by arbitration to circumvent problems at the World Trade Organization (WTO).
Brussels brought the case against Ankara to the WTO in 2019, challenging Turkey's "localisation requirement". The EU said this forced foreign pharmaceutical producers to move their production to Turkey in order for Turkish consumers to qualify for reimbursement when buying their products in pharmacies.
A WTO panel previously rejected Ankara's arguments and recommended it bring its measures in line with global trade rules. This prompted an appeal by Turkey in April, although the appeal had to go down an untested route.
The WTO's Appellate Body, which would normally hear such appeals, has been unable to issue a ruling since 2020 after former U.S. President Donald Trump's blocked new appointments, a policy the current U.S. administration has not reversed.
The Appellate Body's paralysis means that disputes enter a legal void. To resolve that, the European Union and Turkey agreed to send the case to non-WTO arbitrators and to abide by their findings.
This is the first time an appeal in a WTO dispute has gone down this route.
Arbitrators backed some of Turkey's arguments, but supported the earlier WTO panel finding that the localisation requirement breached global trading rules and advised Turkey to adjust its measure accordingly.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.